default author photo

Susann Theile

University of Copenhagen - Copenhagen University Hospital

Copenhangen

Denmark

  • University of Copenhagen - Copenhagen University Hospital

SCHOLARLY PAPERS

1

DOWNLOADS

77

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R)

Downloads 77 (823,616)

Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R)

Number of pages: 32 Posted: 18 Jul 2022
Inna Markovna Chen, Marco Donia, Christopher Aled Chamberlain, Agnete Witness Præst Jensen, Arianna Draghi, Susann Theile, Kasper Madsen, Jane Preuss Hasselby, Anders Toxværd, Estrid Høgdall, Torben Lorentzen, Eva Wilken, Poul Geertsen, Inge Marie Marie Svane, Julia Sidenius Sidenius Johansen and Dorte Nielsen
University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital and University of Copenhagen - Copenhagen University Hospital
Downloads 45 (1,144,483)

Abstract:

Loading...

Pancreatic cancer, nivolumab, tocilizumab, SBRT.

Phase 2 Study of Ipilimumab, Nivolumab, and Tocilizumab Combined with Stereotactic Body Radiotherapy in Patients with Refractory Pancreatic Cancer (TRIPLE-R)

Number of pages: 26 Posted: 29 Jul 2022
Inna Markovna Chen, Marco Donia, Christopher Aled Chamberlain, Agnete Witness Præst Jensen, Arianna Draghi, Susann Theile, Kasper Madsen, Jane Preuss Hasselby, Anders Toxværd, Estrid Høgdall, Torben Lorentzen, Eva Wilken, Poul Geertsen, Inge Marie Marie Svane, Julia Sidenius Sidenius Johansen and Dorte Nielsen
University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital, University of Copenhagen - Copenhagen University Hospital and University of Copenhagen - Copenhagen University Hospital
Downloads 32 (1,326,242)

Abstract:

Loading...

Pancreatic cancer * Ipilimumab * Nivolumab * Tocilizumab * Stereotactic body radiotherapy * TRIPLE-R